FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesEAP 101: Introduction to EAP
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning, Project Management
Presentation
Members
Examining Technology-Driven Trends in the Clinical Supply Chain
Topics: Pharma Industry, Technology
Position Paper
Free
Pelican webinar - Impact of COVID-19 on Cold Chain
Topics: Cold Chain, Supply Chain
Webinar
Free
